Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States

Farrukh Awan, Nadine Zawadzki, Anna Teschemaker, Kathy Wojtas, David Satre, Vikram Shetty, Dipen Patel, Fady Fam, Ryan Crowley, Jason Shafrin

Blood (2025) 146 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2025-2627

Published: 2025

Journal Articles

Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy

Jing-Zhou Hou, Rushir Choksi, Anna Rui, Vikram Shetty, Anna Teschemaker, Kathy Wojtas, Steven Champaloux, Dipen Patel, Doug Kanovsky, Jeffrey Scott, Aliakbar Dadla, Daniel Allendorf

Blood (2025) 146 (Supplement 1): 4506.

https://doi.org/10.1182/blood-2025-4506

Published: 2025

Journal Articles

Mortality trends in patients with mantle cell lymphoma with or without a COVID-19 diagnosis

Krish Patel, Essam Ibrahim, Yi Han, Anna Teschemaker, Victoria Otero, Anouchka Chelles

Blood (2025) 146 (Supplement 1): 8055.

https://doi.org/10.1182/blood-2025-8055

Published: 2025

Journal Articles

Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis

Preetesh Jain, Anna Teschemaker, Essam Ibrahim, Taavy Miller, Danni Zhao, Ayush Kris, Ahmed Sawas, Debbie Adkins, Anouchka Chelles, Victoria Otero, Tycel Phillips

Blood (2025) 146 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2025-4482

Published: 2025

Journal Articles

A Real-World Comparative Analysis of Hypertension and Time to Treatment Failure with Acalabrutinib Vs Ibrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Daniel A. Ermann, George Dranitsaris, Sibel Blau, Aaron Peevyhouse, Heather Neuhalfen, Alan SM Yong, Tina K. Wahlstrom, Samantha L. Thompson, Anna Teschemaker, Vikram Shetty, Mayur S. Narkhede

Blood (2024) 144 (Supplement 1): 6367.

https://doi.org/10.1182/blood-2024-210396

Published: 2024

Journal Articles

Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Krish Patel, Anna Teschemaker, Hongping Tian, Nick Pyrih, Geert Kolvenbag, Shweta Patel, Svea K. Wahlstrom, Lianzhou Cui

Blood (2024) 144 (Supplement 1): 7744.

https://doi.org/10.1182/blood-2024-194523

Published: 2024

Journal Articles

Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets

Brittaney-Belle Elizabeth Gordon, Svea K. Wahlstrom, Anna Teschemaker, Rachel H. Mackey, Diana DeVincenzo, Leslie A. Carabuena, Samantha L. Thompson, Ning A. Rosenthal, Javid J. Moslehi

Blood (2024) 144 (Supplement 1): 5105.

https://doi.org/10.1182/blood-2024-198724

Published: 2024

Journal Articles

Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Javid J. Moslehi, Svea K. Wahlstrom, Anna Teschemaker, Rachel H. Mackey, Diana DeVincenzo, Leslie A. Carabuena, Samantha L. Thompson, Brittaney-Belle Elizabeth Gordon, Ning A. Rosenthal

Blood (2024) 144 (Supplement 1): 5109.

https://doi.org/10.1182/blood-2024-198681

Published: 2024

Journal Articles

Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma

Ryan W Jacobs, Anna Teschemaker, Shweta Hakre, Hongping Tian, Nick Pyrih, Svea K. Wahlstrom, Lianzhou Cui

Blood (2023) 142 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2023-174974

Published: 2023

Journal Articles

Patient and Physician Preferences for Fixed-Duration Vs Treatment to Progression Chronic Lymphocytic Leukemia (CLL) Treatments: Results from a Multi-Country Discrete Choice Experiment

Bersabeh Sile, Dahbia Horchi, Bleuenn Rault, Emily Mulvihill, Kathleen Beusterien, Anna Teschemaker, Katherine Stewart, Paulo Andre P. Palhares De Miranda, Xavier Guillaume

Blood (2023) 142 (Supplement 1): 6528.

https://doi.org/10.1182/blood-2023-177690

Published: 2023

Journal Articles

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lindsey E. Roeker, Yi Han, Kellie J. Ryan, Anna Teschemaker, Anthony R. Mato

Blood (2022) 140 (Supplement 1): 7025–7027.

https://doi.org/10.1182/blood-2022-163534

Published: 2022

Journal Articles

Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A US Real-World Retrospective Cohort Study

Shreekant Parasuraman, Anna Teschemaker, Jonathan K. Kish, Kristin M. Savill, Philomena Colucci

Blood (2022) 140 (Supplement 1): 6854–6855.

https://doi.org/10.1182/blood-2022-162320

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States

Real-world incidence of treatment-emergent cardiovascular events among chronic lymphocytic leukemia/small lymphocytic lymphoma patients receiving acalabrutinib or zanubrutinib monotherapy

Mortality trends in patients with mantle cell lymphoma with or without a COVID-19 diagnosis

Real-world treatment patterns and clinical outcomes in high-risk Mantle Cell Lymphoma: A retrospective analysis

A Real-World Comparative Analysis of Hypertension and Time to Treatment Failure with Acalabrutinib Vs Ibrutinib in Treatment-Naïve Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets

Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma

Patient and Physician Preferences for Fixed-Duration Vs Treatment to Progression Chronic Lymphocytic Leukemia (CLL) Treatments: Results from a Multi-Country Discrete Choice Experiment

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 ( FGFR1 ) Rearrangement (MLN FGFR1 ): A US Real-World Retrospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only